Frankfurt - Delayed Quote EUR
Arrowhead Pharmaceuticals, Inc. (HDP1.F)
14.49
+0.31
+(2.15%)
As of 8:20:02 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 15 | 16 |
| Avg. Estimate | 29.01M | 104.6M | 695.31M | 285.94M |
| Low Estimate | -- | -- | 545.2M | 94M |
| High Estimate | 134.7M | 303.3M | 914.5M | 466.95M |
| Year Ago Sales | -- | -- | 3.55M | 695.31M |
| Sales Growth (year/est) | 0.00% | 0.00% | 19,480.80% | -58.88% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| HDP1.F | -- | -- | -- | -- |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/20/2025 |
| Maintains | Citigroup: Neutral to Neutral | 5/13/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/13/2025 |
| Reiterates | B. Riley Securities: Buy to Buy | 2/14/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/12/2025 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/11/2025 |